Publication Date
8-1-2020
Journal
Clinical Cancer Research
DOI
10.1158/1078-0432.CCR-19-1997
PMID
32299820
PMCID
PMC7415520
PubMedCentral® Posted Date
2-1-2021
PubMedCentral® Full Text Version
Author MSS
Published Open-Access
yes
Keywords
Aged, Antineoplastic Combined Chemotherapy Protocols, Cross-Over Studies, Dexamethasone, Drug Administration Schedule, Drug Resistance, Neoplasm, Female, Follow-Up Studies, Humans, Infusions, Intravenous, Male, Middle Aged, Multiple Myeloma, Neoplasm Recurrence, Local, Oligopeptides, Progression-Free Survival
Abstract
PURPOSE: Treatment of multiple myeloma has evolved tremendously and optimal utilization of available therapies will ensure maximal patient benefits.
PATIENTS AND METHODS: We report the Southwest Oncology Group randomized phase II trial (S1304) comparing twice weekly low-dose (27 mg/m
RESULTS: Among 143 enrolled patients, of whom 121 were eligible and analyzable, the overall response rate was 42.8%, with no significant difference between the arms (
CONCLUSIONS: This randomized trial did not support a benefit of fixed duration, twice weekly 56 mg/m